Immunovant (IMVT) Expected to Post Quarterly Earnings on Friday

Immunovant (NASDAQ:IMVT) is expected to be announcing its Q3 2026 results before the market opens on Friday, February 6th. Analysts expect Immunovant to post earnings of ($0.71) per share for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earning report for the latest details on the call scheduled for Friday, February 6, 2026 at 8:00 AM ET.

Immunovant (NASDAQ:IMVT) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.01). During the same quarter in the previous year, the firm posted ($0.74) EPS. On average, analysts expect Immunovant to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Immunovant Stock Up 1.5%

IMVT opened at $26.45 on Friday. Immunovant has a 52-week low of $12.72 and a 52-week high of $27.80. The company has a 50 day moving average of $25.36 and a two-hundred day moving average of $20.43. The company has a market cap of $4.64 billion, a P/E ratio of -9.31 and a beta of 0.57.

Insider Activity

In other news, insider Tuyl Christopher Van sold 10,813 shares of the firm’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $26.91, for a total value of $290,977.83. Following the transaction, the insider directly owned 149,930 shares in the company, valued at approximately $4,034,616.30. This trade represents a 6.73% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CTO Jay S. Stout sold 1,977 shares of the business’s stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $26.03, for a total transaction of $51,461.31. Following the sale, the chief technology officer directly owned 197,634 shares of the company’s stock, valued at approximately $5,144,413.02. This represents a 0.99% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 63,868 shares of company stock valued at $1,538,470 over the last quarter. 1.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Deep Track Capital LP boosted its holdings in Immunovant by 2.4% during the third quarter. Deep Track Capital LP now owns 9,728,845 shares of the company’s stock worth $156,829,000 after buying an additional 228,845 shares in the last quarter. Armistice Capital LLC lifted its holdings in shares of Immunovant by 12.2% during the 3rd quarter. Armistice Capital LLC now owns 5,836,000 shares of the company’s stock valued at $94,076,000 after buying an additional 636,000 shares during the last quarter. Two Seas Capital LP boosted its holdings in Immunovant by 22.6% in the third quarter. Two Seas Capital LP now owns 2,762,040 shares of the company’s stock worth $44,524,000 after purchasing an additional 509,268 shares in the last quarter. ADAR1 Capital Management LLC increased its holdings in shares of Immunovant by 319.0% during the 3rd quarter. ADAR1 Capital Management LLC now owns 2,241,753 shares of the company’s stock valued at $36,137,000 after acquiring an additional 1,706,687 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in Immunovant by 48.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,007,700 shares of the company’s stock valued at $17,222,000 after purchasing an additional 329,354 shares during the last quarter. Institutional investors and hedge funds own 47.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Truist Financial upped their price target on shares of Immunovant from $16.00 to $22.00 and gave the stock a “hold” rating in a research report on Thursday, January 8th. Guggenheim restated a “buy” rating and set a $41.00 price objective on shares of Immunovant in a research note on Thursday, December 18th. The Goldman Sachs Group increased their target price on Immunovant from $18.00 to $28.00 and gave the company a “neutral” rating in a research note on Monday, December 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunovant in a research report on Friday, January 9th. Finally, Wolfe Research upgraded Immunovant from a “peer perform” rating to an “outperform” rating and set a $50.00 price target for the company in a report on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Immunovant presently has an average rating of “Moderate Buy” and an average target price of $30.78.

Immunovant Company Profile

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.